Overview

Study of 18F-Florastamin PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer

Status:
RECRUITING
Trial end date:
2026-05-01
Target enrollment:
Participant gender:
Summary
In this study, 18F-Florastamin PET/CT will be performed in patients with suspected recurrence of prostate cancer, to assess the diagnostic performance and safety of 18F-Florastamin PET/CT imaging.
Phase:
PHASE3
Details
Lead Sponsor:
HTA Co., Ltd.
Treatments:
Injections